Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2757
Peer-review started: September 14, 2023
First decision: October 8, 2023
Revised: October 23, 2023
Accepted: November 25, 2023
Article in press: November 25, 2023
Published online: December 27, 2023
Processing time: 104 Days and 2.6 Hours
Peptic ulcer (PU) is an abnormal phenomenon of rupture of the mucosa of the digestive tract, which not only affects patients' normal life but also causes an economic burden due to its high medical costs.
There is an urgent need to improve the management of PU from the treatment model and to provide effective treatment options and new clinical references for patients with the disease.
This study investigated the efficacy of pantoprazole (PPZ) plus perforation repair in patients with PU and its effect on the stress response.
The study subjects were 108 PU patients admitted between July 2018 and July 2022, including 58 patients receiving PPZ plus perforation repair [research group (RG)] and 50 patients given simple perforation repair [control group (CG)]. The efficacy, somatostatin (SS) concentration, stress reaction [malondialdehyde (MDA), lipid peroxide (LPO)], inflammatory indices [tumor necrosis factor (TNF)-α, C-reactive protein (CRP), interleukin (IL)-1β], recurrence, and complications (perforation, hemorrhage, and pyloric obstruction) were compared.
The overall response rate was higher in RG than in CG. RG had markedly elevated SS after treatment, which was higher than that of CG, while MDA, LPO, TNF-α, CRP, and IL-1β were significantly reduced to lower than those in CG. Lower recurrence and complication rates were identified in RG.
Therefore, PPZ plus perforation repair is conducive to enhancing treatment outcomes in PU patients, reducing oxidative stress injury and excessive inflammatory reactions, and contributing to low recurrence and complication rates.
PPZ plus perforation repair is effective in the treatment of PU patients, which can inhibit stress response by down-regulating MDA and LPO and up-regulating SS, alleviate inflammation by down-regulating TNF-α, CRP and IL-1β levels, and help reduce the risk of recurrence and complications. Our paper develops a theoretical foundation for the prevention and treatment of PU patients and provides a new treatment option and direction for the management of the disease.